February 7th, 2025 – Zug, Switzerland: RGCC International is honored to have participated in the DMCCB Basel Symposium 2025, held at the prestigious Biozentrum, University of Basel. The symposium, focusing on the theme “Strategies for Addressing Challenging Targets”, brought together leading scientists in medicinal chemistry and chemical biology.
A major highlight of the event was the presentation of the Cancer Drug Discovery Research Award to two outstanding researchers: Zuzanna Kozicka and Lukas Schneider. The award, supported by RGCC and the Swiss Chemical Society, recognizes exceptional contributions to the field of cancer drug discovery.
On behalf of RGCC, Dr. Wilm Buhr proudly presented the awards in recognition of their groundbreaking work:
- Lukas Schneider shared his pioneering research on BODIPY-Based Photothermal Agents for Cancer Treatment.
- Zuzanna Kozicka presented her cutting-edge work on Molecular Glue Degraders of Cyclin K.
RGCC International congratulates both Lukas Schneider and Zuzanna Kozicka for their exceptional achievements and looks forward to their continued contributions to advancing cancer research and improving patient outcomes.
About RGCC International:
RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine. Today, RGCC is a leading innovator in the field of oncology diagnostics. Using world-leading technology, equipment, and innovative techniques, our team of scientists has developed a range of liquid biopsies that help physicians track cancer progression and tailor treatment plans based on individual patient profiles.
For general inquiries, please contact: office@rgcc-international.com